The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
three additional CTP inhibitors were then taken into late stage clinical development including large cardiovascular outcome trials to summarize the results of that one of them was just flat didn't do anything didn't hurt people but didn't help a second one was stopped early because it really didn't look like it was doing anything helping and the third one was followed through and did show about a disappointing nine percent reduction in cardiovascular events
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.